Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
83.99
+3.55 (4.41%)
At close: Jul 2, 2026, 4:00 PM EDT
83.90
-0.09 (-0.11%)
After-hours: Jul 2, 2026, 7:46 PM EDT

Arrowhead Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 13 analysts polled by S&P Global, Arrowhead Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $89.08. The average 1-year stock price forecast is 6.06% higher than the current stock price, while the lowest is $46 (-45.23%) and the highest is $110 (+30.97%).

Price Target: $89.08 (+6.06%)
Analyst Consensus: Buy
TargetLowAverageMedianHigh
Price$46$89.08$91.5$110
Change-45.23%+6.06%+8.94%+30.97%

Analyst Ratings

The average analyst rating for Arrowhead Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

RatingFeb '26Mar '26Apr '26May '26Jun '26Jul '26
Strong Buy777777
Buy223444
Hold332222
Sell000000
Strong Sell000000
Total121212131313

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$100
BuyReiterates$100+19.06%Jul 1, 2026
Piper Sandler
Piper Sandler
Buy
Reiterates
$110
BuyReiterates$110+30.97%Jun 30, 2026
Morgan Stanley
Morgan Stanley
Buy
Maintains
$100
BuyMaintains$100+19.06%Jun 30, 2026
TD Cowen
TD Cowen
Buy
Maintains
n/a
BuyMaintainsn/an/aJun 30, 2026
Chardan Capital
Chardan Capital
Buy
Maintains
$90
BuyMaintains$90+7.16%Jun 30, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
444.20M
from 829.45M
Decreased by -46.45%
Revenue Next Year
336.29M
from 444.20M
Decreased by -24.29%
EPS This Year
-3.00
from -0.01
EPS Next Year
-4.34
from -3.00
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingSep 30, 2021Sep 30, 2022Sep 30, 2023Sep 30, 2024Sep 30, 2025Sep 30, 2026
Revenue
138.29M243.23M240.74M3.55M829.45M444.20M
Revenue Growth
57.16%75.89%-1.03%-98.53%23,258.15%-46.45%
Gross Profit
138.29M243.23M240.74M3.55M829.45M443.04M
Gross Margin
100.00%100.00%100.00%100.00%100.00%99.74%
Operating Income
-149.04M-178.51M-205.00M-601.08M98.35M-427.72M
Net Income
-140.85M-176.06M-205.28M-599.49M-1.63M-448.82M
EPS
-----0.01-3.00
Free Cash Flow
63.00M-60.64M-251.42M-440.13M96.15M-201.10M
No. Analysts
-----13
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High618.0M
Avg444.2M
Low340.0M

Revenue Growth

Revenue Growth202620272028
High
-25.5%
Avg
-46.4%
Low
-59.0%

EPS Forecast

EPS202620272028
High-1.73
Avg-3.00
Low-3.82

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-